Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is an in vivo gene editing program which targets and eliminates covalently closed circular DNA (cccDNA), the sole source of viral replication, leading to sustained loss of pre-genomic RNA (pgRNA), the precursor for hepatitis B virus (HBV) DNA. ELIMINATE-B is designed to be a curative treatment for chronic hepatitis B infection.
Back to dashboard
Company Information
About this company
Key people
Kevin J. Buehler
Independent Chairman of the Board
Melinda Brown
Independent Director
Geno J. Germano
Independent Director
Shari Lisa Pire
Independent Director
Michael Amoroso
President, Chief Executive Officer, Director
Naresh Tanna
Chief Financial Officer
John Alexander Kelly
Chief Operating Officer
Cassie Gorsuch
Chief Scientific Officer
Cindy Atwell
Chief Development Officer
Jeff Smith
Chief Research Officer
Dario Scimeca
Chief Legal Officer, Secretary
Stanley R. Frankel
Director
Click to see more
Key facts
- Shares in issue27.63m
- EPICDTIL
- ISINUS74019P2074
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$159.26m
- Employees67
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.